Abstracts tagged "phenotypes and psoriatic arthritis"

Abstract Number: 684 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials
Frank Behrens¹, Peter Nash², Laure Gossec³, Soyi Liu Leage⁴, Inmaculada de la Torre⁵, Christophe Sapin⁴, Monika Kurzawa⁶, Gerd R. Burmester⁷ and Josef S. Smolen⁸, ¹Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ²University of Queensland, Brisbane, Australia, ³Sorbonne Universités, Paris, France, ⁴Lilly France, Neuilly sur Seine Cedex, France, Neuilly sur Seine Cedex, France, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Bad Homburg, Germany, ⁷Department of Rheumatology and Clinical Immunolgy, Charité University Hospital, Berlin, Germany, ⁸Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: PsA is a highly heterogeneous chronic inflammatory disease combining a range of musculoskeletal and extra-articular manifestations. Ixekizumab (IXE) is approved for the treatment of…
Abstract Number: 1625 • 2018 ACR/ARHP Annual Meeting
Association of HLA-B Type and Sacroiliitis in Patients with Psoriatic Arthritis
Daniel Kuo¹, Isela Valera², Mihaela Taylor¹, Roy Altman¹, Veena K. Ranganath¹, Thanda Aung¹, James Louie¹ and Suzanne Kafaja¹, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with strong genetic heritability. Class I major histocompatibility complex (MHC) genes have been associated with PsA phenotype…
Abstract Number: 2720 • 2016 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinical Phenotypes in Psoriatic Arthritis
Juan D. Cañete¹, Jose A Pinto-Tasende², Jordi Gratacós³, Rubén Queiro⁴, Carlos Alberto Montilla Morales⁵, Juan Carlos Torre-Alonso⁶, Jose Javier Perez Venegas⁷, Antonio Fernandez-Nebro⁸, Santiago Muñoz⁹, Carlos Gonzalez¹⁰, Daniel Roig¹¹, Pedro Zarco¹², Alba Erra¹³, Jesus Rodriguez¹⁴, Santos Castañeda¹⁵, Esteban Rubio-Romero¹⁶, Georgina Salvador¹⁷, Cesar Diaz-Torné¹⁸, Ricardo Blanco¹⁹, Alfredo Willisch²⁰, Jose Antonio Mosquera²¹, Paloma Vela²², Jesús Tornero²³, Simon Sanchez Fernandez²⁴, Hector Corominas²⁵, Julio Ramírez²⁶, Maria López-Lasanta²⁷, Mireia López²⁸, Raül Tortosa²⁹, Antonio Julià²⁹ and Sara Marsal³⁰, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ³Rheumatology, Hospital de Sabadell, Sabadell, Spain, ⁴H Central de Asturias, Oviedo, Spain, ⁵Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ⁶H Monte Naranco, Oviedo, Spain, ⁷Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁸Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ⁹Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ¹⁰Servicio de Reumatología, Hospital Universitario Gregorio Marañón, MD, PhD, Madrid, Spain, ¹¹Rheumatology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, ¹²H Fundación Alcorcón, Alcorcón, Spain, ¹³CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁵Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ¹⁶Rheumatology, Rheumatology, Seville, Spain, ¹⁷Rheumatology Unit., Hospital Mutua de Terrassa. Barcelona, Barcelona, Spain, ¹⁸Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²⁰Complexo Hospitalario de Ourense, Ourense, Spain, ²¹Servicio de Reumatología, Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain, ²²Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²³Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ²⁴Rheumatology Department, Hospital General La Mancha Centro, Ciudad Real, Spain, ²⁵Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ²⁶Rheumatology, Hospital Clínic, Barcelona, Spain, ²⁷Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²⁸Servicio de Reumatología, Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²⁹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ³⁰Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain
Background/Purpose: Genome-wide association studies (GWAS) in patients and healthy controls have allowed the identification of multiple variants associated with disease risk in Psoriatic Arthritis (PsA).…
Abstract Number: 1575 • 2014 ACR/ARHP Annual Meeting
The Association Between Obesity and Disease Phenotype in Psoriatic Arthritis
Lihi Eder¹, Cheryl Rosen², Vinod Chandran³ and Dafna D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Obesity is associated with an increased risk of developing psoriatic arthritis (PsA) in patients with psoriasis. This study aimed to assess whether obesity is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].